Physician profile
Hermann Escobar
NPI 1437258985
$5,568.55
in general payments reported to CMS, 2019-2025
27 companies · $747 in 2025
The $747 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $782 · 2021: $619 · 2022: $582 · 2023: $639 · 2024: $739 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.03 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,819.43 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $577.88 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.10 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $345.15 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $296.92 | 2019-2025 | |
| Abbott Laboratories | $223.80 | 2023-2025 | Infinity |
| Abbvie INC. | $206.53 | 2021-2025 | |
| Amarin Pharma, INC. | $158.81 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $157.49 | 2019-2020 | |
| Globus Medical, INC. | $153.98 | 2025 | Senza |
| Gilead Sciences, INC. | $142.56 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $125.80 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $119.05 | 2019-2025 | Eliquis |
| Novo Nordisk INC | $115.99 | 2019-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.05 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.12 | 2019-2020 | |
| Horizon Therapeutics Plc | $82.18 | 2019-2020 | |
| Ardelyx, INC. | $75.18 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $69.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.20 | 2019 | |
| Electromed, INC. | $48.02 | 2023-2024 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $45.14 | 2019 | |
| Janssen Biotech, INC. | $38.03 | 2023 | Stelara, Remicade, Simponi Aria |
| Endo Pharmaceuticals INC. | $34.44 | 2019 | |
| Amneal Pharmaceuticals LLC | $25.76 | 2022 | |
| Astellas Pharma US INC | $18.06 | 2020 | |
| Genentech USA, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hermann Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.